Beranda › Purpura Trombositopenik Idiopatik
Uji klinis Purpura Trombositopenik Idiopatik yang merekrut di AS
17 studi untuk Purpura Trombositopenik Idiopatik merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Los Angeles, CA7 studi
- Boston, MA6 studi
- Washington, DC6 studi
- Greenville, NC6 studi
- The Bronx, NY5 studi
- Portland, OR4 studi
- Seattle, WA4 studi
- Houston, TX4 studi
- Durham, NC4 studi
- Rochester, MN4 studi
- Philadelphia, PA3 studi
- Cleveland, OH3 studi
- Cedar Rapids, IA3 studi
- Kansas City, MO3 studi
- New Haven, CT3 studi
- New Orleans, LA3 studi
Berdasarkan negara bagian
- Arkansas3 studi
- California10 studi
- Connecticut3 studi
- Distrik Columbia6 studi
- Florida3 studi
- Illinois4 studi
- Iowa3 studi
- Louisiana4 studi
- Massachusetts6 studi
- Michigan3 studi
- Minnesota5 studi
- Missouri3 studi
- New Jersey4 studi
- New York7 studi
- North Carolina7 studi
- Ohio3 studi
- Oregon4 studi
- Pennsylvania3 studi
- Texas4 studi
- Virginia4 studi
- Washington4 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07421167A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07786077A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06721013Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07549698A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06722235A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)
Menerima pesertaFase 3
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07700238Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07095127Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07104565A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07059000A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06948318OM336 in Autoimmune Cytopenias
Menerima pesertaFase 1
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07083960Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Menerima pesertaFase 1
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06371417Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2026 · NCT07007962Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Menerima pesertaFase 2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 12 Mei 2026 · NCT05070845A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Mei 2026 · NCT06544499Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT04323748Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2025 · NCT06817395Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.